Dilafor is developing tafoxiparin to prepare the cervix and uterus for labour. The treatment is designed to mimic the natural process leading up to the onset of labour and is administered subcutaneously, with the potential to be used at home before hospital admission.

Tafoxiparin has completed phase 2b and is ready for registration-enabling phase 3 development. In January 2026, Dilafor entered into a binding term sheet with the global women’s health company Exeltis, which will fund the continued clinical development and commercialisation in licensed markets.

In brief:

• Phase 2b completed – phase 3 ready
• Over 30% of pregnant women today undergo labour induction
• Exeltis is funding the registration-enabling development